DK1296705T3 - Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom - Google Patents

Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom

Info

Publication number
DK1296705T3
DK1296705T3 DK01947033.5T DK01947033T DK1296705T3 DK 1296705 T3 DK1296705 T3 DK 1296705T3 DK 01947033 T DK01947033 T DK 01947033T DK 1296705 T3 DK1296705 T3 DK 1296705T3
Authority
DK
Denmark
Prior art keywords
alleviation
alzheimer
beta
disease
prevention
Prior art date
Application number
DK01947033.5T
Other languages
Danish (da)
English (en)
Inventor
Ashley Bush
Robert Cherny
Rudolph Emile Tanzi
Original Assignee
Prana Biotechnology Ltd
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prana Biotechnology Ltd, Gen Hospital Corp filed Critical Prana Biotechnology Ltd
Application granted granted Critical
Publication of DK1296705T3 publication Critical patent/DK1296705T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
DK01947033.5T 2000-06-28 2001-06-28 Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom DK1296705T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21477900P 2000-06-28 2000-06-28
US24217700P 2000-10-23 2000-10-23
PCT/AU2001/000786 WO2002000245A1 (en) 2000-06-28 2001-06-28 Neurotoxic oligomers

Publications (1)

Publication Number Publication Date
DK1296705T3 true DK1296705T3 (da) 2012-09-17

Family

ID=26909346

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01947033.5T DK1296705T3 (da) 2000-06-28 2001-06-28 Beta-amyloid-oligomerer til anvendelse til behandling, lindring eller forebyggelse af Alzheimers sygdom

Country Status (10)

Country Link
US (2) US7618634B2 (cg-RX-API-DMAC7.html)
EP (1) EP1296705B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004501204A (cg-RX-API-DMAC7.html)
CN (2) CN1450908A (cg-RX-API-DMAC7.html)
AU (2) AU6882801A (cg-RX-API-DMAC7.html)
CA (1) CA2413354C (cg-RX-API-DMAC7.html)
DK (1) DK1296705T3 (cg-RX-API-DMAC7.html)
ES (1) ES2389811T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ523428A (cg-RX-API-DMAC7.html)
WO (1) WO2002000245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7955812B2 (en) 2004-07-19 2011-06-07 The General Hospital Corporation Methods of diagnosing alzheimer's disease by detecting antibodies to cross-linked β-amyloid oligomers
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
WO2007089335A2 (en) * 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2009048631A1 (en) * 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP2013511734A (ja) * 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
WO2011106732A1 (en) 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN112352170B (zh) * 2018-05-15 2024-08-23 鲍希与洛姆伯股份有限公司 可水提取的眼用装置
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
DE102019129221B4 (de) 2019-10-29 2022-05-12 Chiracon Gmbh Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR20230128606A (ko) * 2022-02-28 2023-09-05 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물
CN117024554A (zh) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 一种Aβ1-42寡聚体存储液的制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
EP1296705A1 (en) 2003-04-02
US20040013680A1 (en) 2004-01-22
US8318171B2 (en) 2012-11-27
CN101411876B (zh) 2013-01-16
EP1296705A4 (en) 2005-04-20
EP1296705B1 (en) 2012-06-13
CA2413354A1 (en) 2002-01-03
WO2002000245A1 (en) 2002-01-03
AU6882801A (en) 2002-01-08
JP2004501204A (ja) 2004-01-15
NZ523428A (en) 2008-03-28
CN101411876A (zh) 2009-04-22
HK1131745A1 (en) 2010-02-05
CN1450908A (zh) 2003-10-22
CA2413354C (en) 2014-04-01
ES2389811T3 (es) 2012-10-31
US20090297538A1 (en) 2009-12-03
AU2001268828C1 (en) 2006-12-14
US7618634B2 (en) 2009-11-17
AU2001268828B2 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
NO20026199L (no) Forbindelser for behandling av Alzheimers sykdom
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
NO20033443D0 (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser
DK1265577T3 (da) Medicinsk eller dentalmedicinsk behandlingsstol
NO20020156L (no) Titanavledede forbindelser, fremstilling og anvendelse derav
FR2805456B1 (fr) Prothese totale de genou, du type dit "postero-stabilisee"
NO20040659L (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
FR2810540B1 (fr) Nouvelles preparations cosmetiques ou hygieniques sous forme de dispersion
NO20033801D0 (no) Karbamatforbindelser for anvendelse ved forebygging eller behandling av psykotiske forstyrrelser
NO20032597D0 (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
NO20024746D0 (no) Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
ITRM20000556A0 (it) S-adenosilmetionina e suoi derivati per il trattamento e la prevenzione della malattia di alzheimer.
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
FR2800285B1 (fr) Technologie medicale
PT1408035E (pt) Metodo de preparacao de derivativos de 1.5-diaril-3-trifluorometilo-delta2-pirazolinas que sejam racemicos e enanciomericamente puros
NO20040815L (no) Anvendelse av antroquinoner i behandling av nyresykdom.
AR027958A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades vasculares, que comprende propionil l-carnitina y coenzima q10